Subsequently, other PD-1 inhibitors (pembrolizumab and camrelizumab) have got favorable results in the treatment of advanced HCC in recent clinical trials (Zhu et al., 2018; Qin et al., 2020). Here, PDCD1 is linked to hepatocellular carcinoma.